Biotech Companies Report Q1 Results: Neuronetics Beats Consensus, Voyager Therapeutics Surpasses Expectations, Y-mAbs Therapeutics Outperforms Estimates
- May 09th, 2023
- 561 views
Neuronetics, Inc. (Nasdaq: STIM) has reported a Q1 loss of $0.38 per share, which was slightly better than the consensus loss of $0.39 per share. As of this writing, $STIM is trading at $2.89, up by 31.36% or $0.69.
Meanwhile, Voyager Therapeutics, Inc. (Nasdaq: VYGR) has reported Q1 EPS of $2.94, which exceeded the consensus estimate of $0.77. This positive news has resulted in a surge in the company's stock price, with $VYGR trading at $10.36, up by 24.67% or $2.05.
In other news, Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB) has reported a Q1 loss of $0.15 per share, which was better than the consensus loss of $0.32 per share. This has resulted in a positive trend for the company's stock price, with $YMAB trading at $8.55, up by 26.29% or $1.78.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
FTC Takes Action to Prevent Anticompetitive Arrangement in Beretta, Ruger Deal
September 16th, 2026Why Opponent Preparation Matters for Post-Graduate Athletes
September 16th, 2026The Work Behind the Game: How Football Teams Prepare to Compete
September 15th, 2026NJCP Operates on a Prep Model Built Around a Full Season
September 14th, 2026Earnings Preview: High Tide, Kestra Medical, and RF Industries in Focus
September 12th, 2026
Member Login